Here's Why You Should Buy Willis Towers Watson Stocks Now
Zacks Investment Research | Dec 17, 2018 10:34PM ET
Willis Towers Watson Public Limited Company (NASDAQ:WLTW) remains well-poised for growth, banking on solid segmental performance, high retention level and sturdy capital position, aiding capital deployment. This Zacks Rank #2 (Buy) company is a leading global advisory, broking and solutions company.
Organic growth across segments and accretions from acquisitions, coupled with solid customer retention and growing new business, should continue to drive improvement in revenues. Constant currency revenue growth is estimated to be around 4% in 2018.
Solid segmental outlook too raises optimism about the stock. Growth is estimated in the low-single digit for Human Capital & Benefits, Corporate Risk & Broking, and Investment, Risk & Reinsurance while the same for Benefits Delivery & Administration is projected in the mid- to a high-single digit.
The company’s exchange business also gained momentum. While already 0.3 million lives have been enrolled for 2019, the company remains upbeat about long-term growth of this business.
Given a solid capital position, the company has been pursuing initiatives to ramp up growth. Its inorganic story remains impressive to help it expand geographically as well as add capabilities.
Shares of Willis Towers Watson have gained 0.4% year to date, underperforming the .
Arthur J. Gallagher provides insurance brokerage, consulting, and third party claim settlement and administration services to entities in the United States and internationally. The company delivered positive surprise of 1.30% in the last reported quarter.
eHealth provides private online health insurance exchange services to individuals, families, and small businesses in the United States and China. The company delivered positive surprise of 50.0% in the last reported quarter.
MetLife engages in the insurance, annuities, employee benefits, and asset management businesses. The company pulled off a positive surprise of 10.40% in the last reported quarter.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.